Elicio Therapeutics, Inc.ELTXEarnings & Financial Report
Elicio Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies leveraging its proprietary amphiphile technology platform. Its pipeline includes targeted cancer vaccines and immunomodulatory candidates addressing both solid tumors and hematological malignancies, serving global oncology patient communities.
ELTX Q1 FY2023 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-7.8M
Net Profit
$-8.0M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-24.77
Elicio Therapeutics, Inc. Q1 FY2023 Financial Summary
Elicio Therapeutics, Inc. reported revenue of $0 for Q1 FY2023, with a net profit of $-8.0M (down 13.7% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-8.0M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q1 FY2023 |
Elicio Therapeutics, Inc. Annual Revenue by Year
Elicio Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $2.3M).
Elicio Therapeutics, Inc. Quarterly Revenue & Net Profit History
Elicio Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2023 | $0 | — | $-8.0M | N/A |
| Q4 FY2022 | $0 | — | $-6.7M | N/A |
| Q3 FY2022 | $0 | — | $-7.2M | N/A |
| Q2 FY2022 | $653.0K | +20.9% | $-7.3M | -1117.8% |
| Q1 FY2022 | $1.6M | +344.2% | $-7.1M | -428.4% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Revenue | $1.6M | $653000 | $0 | $0 | $0 |
| YoY Growth | 344.2% | 20.9% | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Assets | $81.3M | $70.8M | $61.3M | $22.7M | $41.8M |
| Liabilities | $14.1M | $11.1M | $11.1M | $13.7M | $2.1M |
| Equity | $-81.4M | $-88.6M | $-95.7M | $-102.1M | $-109.9M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | |
|---|---|---|---|---|---|
| Operating CF | $-15.7M | $6.1M | $-5.4M | $-7.3M | $-8.1M |